Study of the Safety and Efficacy of Natural Genome Reconstruction Technology of Hematopoietic Stem Cells in Adult Patients
Launched by S.LAB (SOLOWAYS) · Mar 10, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This pilot study, titled "Pilot Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Natural Genome Reconstruction Technology in Hematopoietic Stem Cells in Adult Patients," investigates the use of hDNAgr technology-which involves the administration of fragmented therapeutic double-stranded DNA-to achieve natural genomic reconstruction in hematopoietic stem cells. The hypothesis is that this intervention will lead to a safe and controlled correction of damaged genomic regions and telomere elongation, thereby improving hematopoietic parameters (evidenced by restor...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • . Men and women aged 45 to 65 years inclusive (optimal age range for a pilot study of the effect on aging processes).
- • Confirmed absence of serious chronic diseases in the decompensation stage (based on the results of a standard clinical and laboratory examination).
- • No history of malignant neoplasms over the past 5 years. Written informed consent to participate in the study. Willingness to comply with the study protocol, including attending all scheduled visits and undergoing the required diagnostic procedures.
- Exclusion Criteria:
- • Pregnancy, lactation, or planning a pregnancy during the study.
- • The presence of immunodeficiency states (HIV infection, severe autoimmune diseases, etc.) in the acute stage.
- • Decompensated cardiovascular, hepatic, renal pathologies (a conclusion from a therapist or a specialized specialist is required).
- • Take immunosuppressants, corticosteroids or chemotherapeutic drugs within 3 months before screening.
- • Alcohol or drug addiction, confirmed by medical documents or identified during screening.
- • Participation in other clinical trials 30 days before inclusion or planned participation during this study.
- • Observation plan, duration of Follow-Up and number of visits
About S.Lab (Soloways)
s.lab (soloways) is a pioneering clinical trial sponsor dedicated to advancing medical research through innovative study designs and robust methodologies. With a focus on enhancing patient outcomes, s.lab (soloways) collaborates closely with healthcare professionals, regulatory bodies, and trial participants to ensure the highest standards of ethical conduct and scientific integrity. Leveraging cutting-edge technology and data analytics, the organization aims to streamline the clinical trial process, facilitating the rapid development of effective therapies across various therapeutic areas. Committed to transparency and excellence, s.lab (soloways) is at the forefront of transforming clinical research into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported